EQT
64
5
EXC
69
-3
MS
58
5
ESS
51
4
ABT
63
3
MDT
53
-3
ECL
45
3
CAT
48
4
MTB
56
4
ROST
54
7
MAS
63
3
ETN
59
3
CTAS
39
3
FCX
50
2
EMN
48
3
R
62
2
WAT
48
5
MCO
68
4
VZ
49
-5
RSG
73
3
EQT
64
5
EXC
69
-3
MS
58
5
ESS
51
4
ABT
63
3
MDT
53
-3
ECL
45
3
CAT
48
4
MTB
56
4
ROST
54
7
MAS
63
3
ETN
59
3
CTAS
39
3
FCX
50
2
EMN
48
3
R
62
2
WAT
48
5
MCO
68
4
VZ
49
-5
RSG
73
3
Financhill
Back

Amylyx Pharmaceuticals 10K Form

Sell
33

AMLX
Amylyx Pharmaceuticals

Last Price:
$3.76
Seasonality Move:
-28.38%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive AMLX News And Ratings

See the #1 stock for the next 7 days that we like better than AMLX

AMLX Financial Statistics

Sales & Book Value

Annual Sales: $87.4M
Cash Flow: $-59M
Price / Cash Flow: 8.66
Annual Sales: $2.40
Price / Book: 2.03

Profitability

EPS (TTM): -4.44000
Net Income (TTM): $-301.7M
Gross Margin: $-37.3M
Return on Equity: -109.32%
Return on Assets: -88.16%

Amylyx Pharmaceuticals Earnings Forecast

Key Amylyx Pharmaceuticals Financial Ratios

  • The Gross Profit Margin over the past 4 years for AMLX is -42.65%.
  • The Selling, General & Administrative Expenses for AMLX have been equal to 130.86% of Gross Profit Margin.
  • The Research & Development expenses have been 160.56% of Revenue.
  • Per Share Earnings over the last 6 years have been positive in 1 years.

Amylyx Pharmaceuticals Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: AMLX
Website: amylyx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 6.67
Quick Ratio: 6.23

Price-to-Earnings

Trailing P/E Ratio: 4.29
Forward P/E Ratio: 0

AMLX Technical Analysis vs Fundamental Analysis

Sell
33
Amylyx Pharmaceuticals (AMLX) is a Sell

Is Amylyx Pharmaceuticals a Buy or a Sell?